Myeloproliferative Neoplasms | Specialty

The OncLive Myeloproliferative Neoplasms condition center is a comprehensive resource for clinical news and expert insights on myeloproliferative neoplasms, including myelofibrosis, polycythemia vera, and essential thrombocythemia. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in myeloproliferative neoplasms.

Dr. Jamieson on the Importance of Treating at Diagnosis in Myelofibrosis

August 12th 2021

Catriona Jamieson, MD, PhD, discusses the importance of treating patients with myelofibrosis at diagnosis.

Momelotinib Improves Transfusion Independence Rates Vs Ruxolitinib in Anemic, JAK Inhibitor–Naïve Myelofibrosis

August 12th 2021

Jean-Jacques Kiladjian, MD, PhD, discusses the effectiveness of momelotinib compared with ruxolitinib in patients with myelofibrosis who have anemia and are naïve to JAK inhibitors.

Myelofibrosis: Treatment Planning and Management

August 11th 2021

Criteria and assessments that can be used to help clinicians select treatment and monitor patients on therapy for myelofibrosis.

Treatment Approaches for Myelofibrosis

August 11th 2021

Pankit Vachhani, MD, comments on goals of therapy for patients with myelofibrosis and highlights traditional treatment approaches.

Risk Stratification: Primary Myelofibrosis

August 11th 2021

An overview of risk stratification models available to assess and classify patients with primary myelofibrosis.

Rusfertide Could Represent New Therapeutic Option in Polycythemia Vera

August 6th 2021

Marina Kremyanskaya, MD, PhD, discussed the results of the phase 2 PTG-300-04 trial, which were presented at the European Hematology Association 2021 Virtual Congress, and the potential for rusfertide as a treatment option for patients with polycythemia vera.

Allogeneic HSCT Linked With Favorable Survival Outcomes in Myelofibrosis

August 5th 2021

Though there have been significant and recent therapeutic developments for patients with myelofibrosis, allogeneic hematopoietic stem cell transplant remains the sole curative therapeutic modality.

Dr. Mauro on Considerations for Early Treatment Initiation in Myelofibrosis

August 5th 2021

Michael J. Mauro, MD, discusses considerations for early treatment initiation in myelofibrosis.

Future Directions in the Treatment of Polycythemia Vera

August 4th 2021

A thought leader in hematologic malignancies provides key insights into the future of treatment for polycythemia vera by considering the potential role of treatment sequencing or combination therapy.

Ruxolitinib in PV: The RESPONSE-2 Trial

August 4th 2021

Jamile Shammo, MD, FASCP, FACP, continues her discussion of ruxolitinib for polycythemia vera by examining the results of the RESPONSE-2 trial and sharing personal experience managing toxicity in clinic.

Ruxolitinib in PV: The RESPONSE Trial

August 4th 2021

Renowned expert in the management of MPNs, Jamile Shammo, MD, FASCP, FACP, reviews the RESPONSE trial of ruxolitinib in patients with PV and discusses the agent’s safety and efficacy.

The JAK2 Pathway in Polycythemia Vera

August 4th 2021

A specialist in hematologic malignancies provides an overview of the JAK2 pathway as it relates to myeloproliferative neoplasms such as polycythemia vera.

Dr. Rampal on Symptoms of Disease Progression in Myelofibrosis

August 3rd 2021

Raajit K. Rampal, MD, PhD, discusses symptoms of disease progression in myelofibrosis.

PV Treatment Options and Dosing

July 28th 2021

Jamile Shammo, MD, FASCP, FACP, shares insight into the currently available treatment options for polycythemia vera and examines how treatment intolerance and/or resistance can impact the therapeutic approach.

Risk Stratification and Treatment Considerations in PV

July 28th 2021

A key opinion leader in the management of polycythemia vera discusses risk stratification and reflects on factors that influence the decision to observe or treat the patient’s disease.

Myeloproliferative Neoplasms: Diagnosing Polycythemia Vera

July 28th 2021

An expert in hematologic malignancies, Jamile Shammo, MD, FASCP, FACP, provides an overview of the 2016 WHO diagnostic criteria for polycythemia vera and considers the role of genetic testing.

Dr. Jamieson on Symptom Management in Myelofibrosis

July 21st 2021

Catriona Jamieson, MD, PhD, discusses symptom management in patients with myelofibrosis.

Dr. Kiladjian on Improving Transfusion-Independence Rates With Momelotinib in Myelofibrosis

July 21st 2021

Jean-Jacques Kiladjian, MD, PhD, discusses the potential utility of momelotinib in improving transfusion-independence rates in myelofibrosis.

Bone Marrow Transplant for Patients With MF

July 20th 2021

Expert panelists review important disease-related and patient-related factors when considering bone marrow transplant in patients with primary myelofibrosis.

Fedratinib for Patients With Primary Myelofibrosis

July 13th 2021

Pankit Vachhani, MD, guides a discussion on the FDA approval of fedratinib and reviews how it has affected the therapeutic landscape for patients with primary myelofibrosis.